Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews' Q3 Revenues, Net Loss Rise

NEW YORK (GenomeWeb News) – Biomarker test developer GeneNews has reported an increase in its third-quarter 2008 revenue to C$300,000 (US$246,000) from C$200,000 for last year’s third quarter.
The Toronto-based firm said that revenue in the most recent quarter came from a collaboration with an Asian biomedical consortium to identify and validate a set of biomarkers for prostate diseases. That deal was worth US$2 million to GeneNews. The firm’s Q3 2007 revenue came from a collaboration with Pfizer that has since been completed.
GeneNews posted a net loss of C$3.9 million, or C$.07 per share, compared to a net loss of C$3 million, or C$.05 per share, for the third quarter of 2007.
The company’s R&D costs increased around 8 percent to C$2.6 million from C$2.4 million, while its general and administrative spending was flat at C$700,000.
GeneNews finished the quarter with cash and cash equivalents of C$3.2 million.
The firm announced last week that it will cut 40 percent of its workforce in Canada as part of a restructuring effort. GeneNews said that its Canadian operations would focus on Canadian and US commercialization of its lead product, ColonSentry, a genomics-based test for determining a person’s risk for colorectal cancer. Meanwhile, its R&D activities, including patient sample accrual, will be moved to its operations in Asia.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.